Oligodendrocytes may show early immune-like changes in multiple sclerosis (MS), according to findings from a mouse study.

Please provide your email address to receive an email when new articles are posted on . Patients with MS had lower corneal nerve fiber density, corneal nerve branch density and corneal nerve fiber ...

Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.

Jazz Pharmaceuticals JAZZ announced that its phase III study — RELEASE MSS1 — evaluating nabiximols oromucosal spray (Sativex in ex-U.S. markets) for clinical measures of spasticity in individuals ...

Proteomics helped uncover molecular signatures of multiple sclerosis up to seven years before symptom onset, paving the way ...

Differences in the complexity of the EEG signal (yellow and red colors) in a specific brain area between the group with advanced multiple sclerosis and the control group, and multifractal spectra ...

Criteria used by neurologists to assess for multiple sclerosis (MS) in adults may fail to identify the illness in children with imaging suspicious for the disease, an oversight that could delay ...

While expressing disappointment, William Blair analysts were unsurprised by the Phase II failure, having assigned the VISTA study a high level of risk given the “mixed” performance of a similar drug ...

The results from more than one-third of late-stage clinical trials that tested multiple sclerosis drugs were never published in peer-reviewed journals — and studies with negative or inconclusive ...

FRANKFURT, April 30 (Reuters) - Merck KGaA has started a mid-stage trial to evaluate the safety and efficacy of atacicept in patients with relapsing multiple sclerosis, the German drugs and chemicals ...

Understanding changes, seeking support, and staying connected can help caregivers adapt to the challenges of secondary progressive MS.

Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, cutting the number of relapses compared to another treatment over nearly ...